San Diego, CA, March 19, 2012 - Binding Site is pleased announce the addition of its new Rheumatoid Factor (RF)/IgG Absorbent Reagent to its broad offering for IVD manufacturers.
Specifically designed for use in conjunction with immunodiagnostic assays, Binding Site’s RF/IgG Absorbent Reagent is distinctively formulated to remove both IgG and RF-IgM molecules from human serum. In principle, the reagent effectively prevents these bodily components from non-specific binding within the test sample. This eliminates certain interference effects found with some immunodiagnostic assays which are looking to quantitatively determine human antigen-specific IgM immunoglobulin concentrations, as found in various diagnostic disease states. As such, the RF/IgG Absorbent Reagent serves to enhance overall specificity by reducing both the amount of false positive test results from native IgG components and the amount of false negative test results from native RF-IgM components.
Binding Site’s new RF/IgG Absorbent Reagent demonstrates outstanding performance characteristics in routine use. The reagent is available as a ready-to-use, fully liquid stable product and is offered in a number of convenient, operator-oriented packaging configurations, including bulk-sized formats.
Binding Site serves the in vitro diagnostic and life science markets with a comprehensive line of innovative products.
For additional information, contact
The Binding Site,
Inc. at 5889 Oberlin Drive – Suite 101,
San Diego, CA 92121 USA.
Phone: 800-633-4484;
FAX: 858-453-9189;
Email: [email protected]
Please visit our website at www.thebindingsite.com.